Navigation Links
Paul Capital Healthcare Leads Panel on Strategic Financing

NEW YORK and LONDON, June 9 /PRNewswire/ -- Paul Capital Healthcare today announced that London-based partner Ken Macleod, Ph.D., will moderate a panel on strategic biotechnology financing at the BioFinance and BioInnovate Europe 08 conference. Designed to familiarize participants with how to use revenue streams as a strategic approach to financing, the panel, "Feeding the Beast: Structured Revenue Financing as a Strategy for Meeting Biotechnology's Capital Needs," is scheduled for 3:00 pm BST today. The conference, which is sponsored by the Biotechnology Industry Association, will be held at the Royal College of Physicians in London.

In addition to Dr. Macleod, the panel also will include Kristian Wiggert, Partner in the London office of Morrison & Foerster, and Steven Powell, Ph.D., Chief Executive Officer of Plethora Solutions Holdings PLC. Dr. Macleod will provide an overview and case studies of royalty and structured revenue financing transactions, Mr. Wiggert will discuss the legal considerations of these transactions and Dr. Powell will speak on the strategic rationale and mechanics of his company's recent revenue interest agreement with Paul Capital Healthcare.

"Structured revenue financing and royalty monetization transactions are becoming a standard financing strategy because they provide access to non- dilutive capital under flexible terms that can be structured to meet diverse objectives," said Dr. Macleod. "Companies and institutions can structure these transactions to provide capital for near-term initiatives while retaining a substantial portion of the long-term value and upside potential of their royalty and revenue streams. This panel presentation is designed to provide participants with real-life examples of how these transactions fit into an overall financial and asset management strategy and the opportunity to learn from those with first-hand knowledge of the process."

About Paul Capital Healthcare and Paul Capital Partners

Through its funds, Paul Capital Healthcare is one of the largest dedicated healthcare investors globally, with more than $1.4 billion in equity capital commitments and debt facilities under management. Combined, the Paul Capital Healthcare funds have invested more than $940 million in the pharmaceutical, biotechnology, and medical device sectors. These investments are focused on commercial stage companies and products, and consist of investments in the form of royalties, revenue interests, debt and equity. Additional information on Paul Capital Healthcare can be found at Paul Capital Partners manages nearly $5 billion in equity capital commitments for its three investment platforms, which include Paul Capital Healthcare, Private Equity Secondaries and Top Tier Fund-of-Funds. The firm has offices in New York, San Francisco, Paris, London, Hong Kong, and Sao Paolo.

Contact Information:

Paul Capital Healthcare Tel: +44 (0) 20 7514 0754

Ken Macleod, Partner

Lazar Partners Tel: +1-646-871-8487

Stephanie Seiler Tel: +1-206-713-0124


SOURCE Paul Capital Healthcare
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. BioSpace Releases the 2008 BioCapital(TM) Hotbed Campaign
2. Novavax CEO to Present at FBR Capital Markets 12th Annual Spring Investor Conference
3. CryoLife to Present at FBR Capital Markets Annual Spring Investor Conference
4. Inverness Medical Innovations to Present at FBR Capital Markets 12th Annual Spring Investor Conference on May 28, 2008
5. Amylin Pharmaceuticals to Present at FBR Capital Markets Investor Conference
6. SuperGen to Present at FBR Capital Markets 12th Annual Spring Investor Conference on May 29, 2008
7. Record Venture Capital and Heated Deal Environment Propel Global Biotechnology Industry Forward in 2007
8. MGT Capital Investments Reports First Quarter 2008 Financial Results and Provides Update on Recent Developments
9. Launch of Fountain Healthcare Partners, a Life Science Venture Capital Firm
10. Vernalis and Paul Capital Healthcare Sign euro 18.4 Million Financing Agreement
11. SPO Medical Retains American Capital Ventures for Investor Relations Services
Post Your Comments:
(Date:10/11/2017)... ... October 11, 2017 , ... ... implantation and pregnancy rates in frozen and fresh in vitro fertilization (IVF) ... and maternal age to IVF success. , After comparing the results from the ...
(Date:10/10/2017)... ... October 10, 2017 , ... Dr. Bob Harman, founder ... local San Diego Rotary Club. The event entitled “Stem Cells and ... had 300+ attendees. Dr. Harman, DVM, MPVM was joined by two human doctors: ...
(Date:10/9/2017)... 9, 2017  BioTech Holdings announced today identification ... its ProCell stem cell therapy prevents limb loss ... Company, demonstrated that treatment with ProCell resulted in ... as compared to standard bone marrow stem cell ... in reduction of therapeutic effect.  ...
(Date:10/7/2017)... (PRWEB) , ... October 06, ... ... years’ experience providing advanced instruments and applications consulting for microscopy and surface ... expertise in application consulting, Nanoscience Analytical offers a broad range of contract ...
Breaking Biology Technology:
(Date:4/6/2017)... , April 6, 2017 Forecasts ... ANPR, Document Readers, by End-Use (Transportation & Logistics, Government ... Oil, Gas & Fossil Generation Facility, Nuclear Power), Industrial, ... Other) Are you looking for a definitive ... ...
(Date:4/5/2017)... 2017 Today HYPR Corp. , leading ... component of the HYPR platform is officially FIDO® ... security architecture that empowers biometric authentication across Fortune 500 ... secured over 15 million users across the financial services ... home product suites and physical access represent a growing ...
(Date:4/4/2017)... , April 4, 2017   EyeLock LLC ... announced that the United States Patent and Trademark Office ... broadly covers the linking of an iris image with ... transaction) and represents the company,s 45 th issued ... patent is very timely given the multi-modal biometric capabilities ...
Breaking Biology News(10 mins):